Main outcome measure: Median duration of locoregional control
ERBITUX with RT increased median duration of locoregional control by 0.8 years vs RT alone (2.0 years vs 1.2 years, respectively; HR=0.68 [95% CI: 0.52-0.89]; P=0.005).1
An OS advantage was maintained at 3 and 5 years2,3
- ERBITUX with RT improved OS rate at 3 years vs RT alone; 55% vs 45%, respectively (HR not available)2
- 10% absolute improvement in 3-year survival rate vs RT alone
- ERBITUX with RT improved OS rate at 5 years vs RT alone; 45.6% vs 36.4%, respectively (HR=0.73; 95% CI: 0.56-0.95)3
- 9.2% absolute improvement in 5-year survival rate vs RT alone